Lei Jianping on January 30
Beijing Kangle Guardian Biotechnology Co., Ltd. *** referred to as "Kangle Guard") recently submitted a prospectus to be listed on the Hong Kong Stock Exchange.
Kangle Guardian has been listed on the Beijing Stock Exchange. Once listed on the Hong Kong Stock Exchange, it will be listed in both places at the same time.
In less than 2 years, the net loss exceeded 500 million
HealthGuard is a clinical-stage vaccine developer in China with the world's broadest HPV vaccine portfolio, and is transitioning from biotechnology R&D to commercialization.
The three HPV vaccine combinations of Health Guardian have high commercial visibility and lead the industry to meet the needs of different groups of people for different services. The core product of the near-commercialized trivalent HPV vaccine candidate, designed to protect women in East Asia, is expected to be submitted to the BLA in China by the end of 2024.
The Phase III 9-valent HPV vaccine candidate is another core product and is expected to be one of the first domestic 9-valent HPV vaccine candidates approved for use in women, with a planned BLA submission in China in 2025, and is also the first domestically produced 9-valent HPV vaccine candidate in China to begin a critical efficacy trial in men.
Connaught Guardian is also actively developing a 9-valent HPV vaccine candidate overseas, conducting a Phase III clinical trial in women in Indonesia, and is expected to submit BLA to BPOM Indonesia in 2025.
Connaught Guardian's Phase I 15-valent HPV vaccine candidate is the most expensive of all HPV vaccines in the world that are commercially available or have obtained IND approval. Health Guard also has six preclinical vaccine candidates in development for disease areas with gaps in medical needs or in urgent need of vaccine upgrades.
According to the prospectus, Kangle Guard's revenue in 2022 will be 1.9 million yuan, and the loss during the period will be 29.3 billion yuan, of which R&D investment is 23.7 billion yuan, and administrative expenses of 79.12 million yuan.
Kangle Guard's revenue in the first nine months of 2023 was 1.6 million yuan, compared with 88 in the same period last year80,000 yuan; The loss for the period was 22.5 billion yuan, compared with a loss of 2100 million yuan. In the first nine months of 2023, the R&D investment of Kangle Guardian was 17.7 billion yuan, and administrative expenses were 65.42 million yuan.
This also means that in less than two years, Kangle Guardian has lost more than 500 million yuan.
As of September 30, 2023, the company had cash and cash equivalents of 25.3 billion yuan. Currently, Connaught Guardian relies primarily on equity financing and debt financing to fund the company's operations and other capital needs.
Tao Tao controls 306% voting rights
The executive directors of Kangle Guardian are Liu Yongjiang, Hao Chunli, and Tao Ran; The non-executive directors are Tao Tao (former name: Tao Tao), Liu Qingli and Ms. Li Hui; The independent non-executive Directors are Dr. Li Xiaojing, Dr. Qiao Youlin and Han Qiang.
In August 2021, Kangle Guardian completed a private placement in ***, raising a total of about RMB 101.6 billion yuan.
As of now, Sirius Holding Group holds 224%, and Jianglin Weihua holds 79%, and Jilin Xinsheng holds 345%, and the shareholding of Baibai Ruiying is 317%, Zhang Ansheng holds 271%；
Yunfeng** and Qianhai Jiancheng hold 259%, Yunnan Huigang Investment *** Yunnan Yunnan Central Hengsheng Investment *** Yuanwang ** respectively holds 181%。
Pursuant to the Irrevocable Concert Agreement dated 16 April 2021 (the "Concert Agreement") and the Supplemental Agreement dated 29 July 2021, the Non-Executive Directors and the controlling shareholders of Sirius Holding Group, Tao Tao, Sirius Holding Group, Xiaojiang Biotech and Jianglin Weihua (the "Concert Parties") agreed to act in concert with each other and to vote with Tao Tao at the general meeting, which expired when only one of the above parties held shares in Connaught Guardian.
Accordingly, as of the Latest Practicable Date, Tao Tao, Sirius Holding Group, Xiaojiang Biotech and Jianglin Weihua are jointly entitled to exercise 3060% of the voting rights.
Lei Di was founded by ** Lei Jianping, if ** please in**.